Application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of prematurity
- 作者: Kariakin M.1, Stepanova E.1,2, Korotkikh S.1,2, Timofeeva N.1, Surtaev S.1
-
隶属关系:
- Multiprofile Clinical Medical Center «BONUM»
- Urals State Medical University
- 期: 卷 16, 编号 3 (2021)
- 页面: 5-10
- 栏目: Original study article
- URL: https://journals.rcsi.science/1993-1859/article/view/90740
- DOI: https://doi.org/10.17816/rpoj90740
- ID: 90740
如何引用文章
详细
AIM: To conduct a retrospective study of the application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of prematurity in Ural State children`s ophthalmological center at State Autonomic Health Institution of the Sverdlovsk Region Multiprofile Clinical Medical Center «BONUM» in Yekaterinburg.
MATERIAL AND METHODS: The study included 17 patients (33 eyes). The gestation age was from 23 to 30 weeks (mean: 26.5±1.7 weeks), birth weight was from 600 to 1850 g (mean: 867±229 g). 8 patients (47%) had APROP, and 9 patients (53%) had ROP stage III, type 1, “plus disease.” Laser coagulation of the avascular areas of the retina as the start in ROP therapy was performed in three patients with APROP (4 eyes, 12.1%). Intravitreal injection of the anti-VEGF ranibizumab was performed in 17 patients (33 eyes), including patients with previous laser coagulation. The age of the patients at the time of injection was from 7.7 to 15.6 weeks (10.5±1.9 weeks), PCA from 32.3 to 39.6 weeks (37.0±1.8 weeks). Patients with stage IVa ROP (5 patients, 6 eyes) underwent 25G or 27G lens sparing vitrectomy.
RESULTS: As a result of the complex treatment of ROP, the following results were obtained: complete regression in 13 patients (28 eyes, 84.8%). Partial regression in two patients (2 eyes, 6.1%). ROP progression to stage V in two patients (3 eyes, 9.1%).
CONCLUSION: Complex treatment of severe stages of active ROP with laser treatment, IVI injections, ranibizumab, and vitrectomy made it possible to preserve vision in 90.9% of patients.
作者简介
M. Kariakin
Multiprofile Clinical Medical Center «BONUM»
Email: mak1@bk.ru
ORCID iD: 0000-0002-3150-5349
SPIN 代码: 9354-7765
MD, PhD
俄罗斯联邦, EkaterinburgE. Stepanova
Multiprofile Clinical Medical Center «BONUM»; Urals State Medical University
Email: odoc@bonum.info
MD, PhD, Associate Professor of the Department of Ophthalmology
俄罗斯联邦, EkaterinburgS. Korotkikh
Multiprofile Clinical Medical Center «BONUM»; Urals State Medical University
编辑信件的主要联系方式.
Email: secretar@mcprof.ru
SPIN 代码: 7326-7197
Dr of Med. Sci., Professor
俄罗斯联邦, EkaterinburgN. Timofeeva
Multiprofile Clinical Medical Center «BONUM»
Email: odoc@bonum.info
doctor-ophthalmologist
俄罗斯联邦, EkaterinburgS. Surtaev
Multiprofile Clinical Medical Center «BONUM»
Email: odoc@bonum.info
MD, doctor-ophthalmologist
俄罗斯联邦, Ekaterinburg参考
- Katargina LA. Retinopatiya nedonoshennykh, sovremennoe sostoyanie problemy i zadachi organizatsii oftal’mologicheskoi pomoshchi nedonoshennym detyam v RF. Russian pediatric ophthalmology. 2012;(1):5-7. (In Russ).
- Katargina LA, Demchenko EN. Novye vozmozhnosti v vedenii patsientov s retinopatiei nedonoshennykh (obzor literatury i analiz sobstvennykh dannykh). Russian pediatric ophthalmology. 2020;13(4):70-74. (In Russ).
- Neroev VV, Katargina LA, editors. Retinopatiya nedonoshennykh. Moscow: IKAR; 2020. (In Russ).
- Zhang G, Yang M, Zeng J, et al. Comparison of Intravitreal Injection of Ranibizumab Versus Laser Therapy for Zone Ii Treatment-Requiring Retinopathy of Prematurity. Retina. 2017;37(4):710-717. doi: 10.1097/IAE.0000000000001241
- Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol. 2015;15:20. doi: 10.1186/s12886-015-0001-7
- Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3
- International Committee for the Classification of Retinopathy of P. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-999. doi: 10.1001/archopht.123.7.991